MedTrace Logo

Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

NCT04217694 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-11-21

No results posted yet for this study

Summary

This early phase I trial studies the feasibility of giving memantine for the reduction of cognitive impairment after radiation therapy in pediatric patients with central nervous system tumors. Memantine may reduce the effects of radiation therapy on memory and thinking.

Conditions

  • Malignant Central Nervous System Neoplasm
  • Primary Central Nervous System Neoplasm

Interventions

BEHAVIORAL

Cogstate Assessment Battery

Complete CogState testing

DRUG

Memantine

Given PO

DRUG

Memantine Hydrochloride

Given PO

Sponsors & Collaborators

Principal Investigators

  • Nadia N. Laack, M.D. · Mayo Clinic

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-17
Primary Completion
2022-09-15
Completion
2024-08-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04217694 on ClinicalTrials.gov